Education
About Us
Working with TipRanks
Follow Us
ADMA Biologics Inc (ADMA)
:ADMA
Total Valuation
ADMA Biologics has a market cap or net worth of $3.49B. The enterprise value is ―.
Market Cap$3.49B
Enterprise Value―
Share Statistics
ADMA Biologics has 238,630,720 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding238,630,720
Owned by Insiders3.19%
Owned by Institutions0.90%
Financial Efficiency
ADMA Biologics’s return on equity (ROE) is 0.57 and return on invested capital (ROIC) is 50.31%.
Return on Equity (ROE)0.57
Return on Assets (ROA)0.40
Return on Invested Capital (ROIC)50.31%
Return on Capital Employed (ROCE)0.32
Revenue Per Employee622.56K
Profits Per Employee288.57K
Employee Count685
Asset Turnover0.87
Inventory Turnover1.22
Valuation Ratios
The current PE Ratio of ADMA Biologics is 18.1. ADMA Biologics’s PEG ratio is -0.03.
PE Ratio18.1
PS Ratio9.37
PB Ratio11.45
Price to Fair Value11.45
Price to FCF36.31
Price to Operating Cash Flow45.71
PEG Ratio-0.03
Income Statement
In the last 12 months, ADMA Biologics had revenue of 426.45M and earned 197.67M in profits. Earnings per share was 0.85.
Revenue426.45M
Gross Profit219.55M
Operating Income138.98M
Pretax Income125.71M
Net Income197.67M
EBITDA147.69M
Earnings Per Share (EPS)0.85
Cash Flow
In the last 12 months, operating cash flow was 64.97M and capital expenditures -24.24M, giving a free cash flow of 40.73M billion.
Operating Cash Flow64.97M
Free Cash Flow40.73M
Free Cash Flow per Share0.17
Dividends & Yields
ADMA Biologics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.94
52-Week Price Change-34.56%
50-Day Moving Average15.37
200-Day Moving Average17.86
Relative Strength Index (RSI)44.34
Average Volume (3m)3.26M
Important Dates
ADMA Biologics upcoming earnings date is Mar 19, 2026, TBA (Confirmed).
Last Earnings DateNov 5, 2025
Next Earnings DateMar 19, 2026
Ex-Dividend Date―
Financial Position
ADMA Biologics as a current ratio of 5.97, with Debt / Equity ratio of 21.04%
Current Ratio5.97
Quick Ratio2.90
Debt to Market Cap0.02
Net Debt to EBITDA-0.14
Interest Coverage Ratio9.98
Taxes
In the past 12 months, ADMA Biologics has paid -71.96M in taxes.
Income Tax-71.96M
Effective Tax Rate-0.57
Enterprise Valuation
ADMA Biologics EV to EBITDA ratio is 26.92, with an EV/FCF ratio of 36.12.
EV to Sales9.32
EV to EBITDA26.92
EV to Free Cash Flow36.12
EV to Operating Cash Flow33.51
Balance Sheet
ADMA Biologics has $61.38M in cash and marketable securities with $83.12M in debt, giving a net cash position of -$21.74M billion.
Cash & Marketable Securities$61.38M
Total Debt$83.12M
Net Cash-$21.74M
Net Cash Per Share-$0.09
Tangible Book Value Per Share$1.48
Margins
Gross margin is 53.00%, with operating margin of 32.59%, and net profit margin of 46.35%.
Gross Margin53.00%
Operating Margin32.59%
Pretax Margin29.48%
Net Profit Margin46.35%
EBITDA Margin34.63%
EBIT Margin32.75%
Analyst Forecast
The average price target for ADMA Biologics is $32.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$32.00
Price Target Upside117.39% Upside
Analyst ConsensusModerate Buy
Analyst Count1
Revenue Growth Forecast27.62%
EPS Growth Forecast202.89%